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HCV genetics and genotypes dictate future antiviral strategies 
Introduction on clinical signs & symptoms 
 
Acute infection with HCV usually only results in mild 
symptoms, and the majority of patients do not experi-
ence any signs at all (Lauer & Walker 2001).  Symp-
toms that may be seen are non-specific – e.g. jaundice, 
nausea and a general feeling of being unwell (Lauer & 
Walker 2001) – and therefore cannot be used to con-
clusively diagnose HCV infection.  The rationale for 
treatment of HCV infection in patients who are symp-
tomatic at the acute infection stage is uncertain, as the 
few individuals who present with symptoms often re-
cover spontaneously (i.e. in the absence of treatment) 
(Pearlman 2004). 
 This acute phase usually progresses to chronic 
infection, which often remains clinically silent (Lauer 
& Walker 2001) for many years until the development 
of severe liver damage (De Francesco et al. 2003).  
The period from infection to the detection of liver 
damage can last over 30 years (Lauer & Walker 2001), 
during which period the patient may unwittingly 
spread the virus to others as they are unaware of their 
infective status.  HCV (Loukatou et al. 2015) infects 
Journal of Molecular Biochemistry (2017) 6, 33-40 © The Author(s) 2017. Published by Lorem Ipsum Press. 
At the end of the 1980s, the hepatitis C virus (HCV) 
was cloned and formally identified as the cause of the 
majority of non-A and non-B hepatitis cases. Today, 
around 170 million people worldwide are infected with 
HCV, making it five times more common than infec-
tion with the human immunodeficiency virus (HIV).  
Several methods exist which mediate the spread of 
infection. One of the most common and efficient is 
sharing or re-using injecting equipment; studies have 
indicated that 80-90% of individuals in some popula-
tions of intravenous drug users test positive in serum 
HCV assays. Contracting HCV from infected blood 
transfusions was also a major cause of infection before 
screening tests were introduced in the early 1990s.  
Other possible, but less common, methods of infection 
transmission include mother-to-child during pregnan-
cy, sexual contact and nosocomial acquisition (for ex-
ample between surgical or dialysis patients).  It ap-
pears that concurrent HIV-1 infection increases the 
risk of HCV transmission via the mother-to-child or 
sexual routes. 
Abstract 
hepatocytes – which leads to the development of pro-
gressive fibrosis in over 50% of cases and cirrhosis in 
15-20% of infected patients (De Francesco et al. 
2003). Cirrhosis itself is a risk factor for hepatocellular 
carcinoma, the most serious consequence of HCV in-
fection; liver cancer develops in 1-4% of cirrhotic 
HCV patients each year (Lauer & Walker 2001). 
 Many additional factors affect the prognosis of 
the HCV-positive patient. Alcohol consumption 
(Pearlman 2004), male sex (Lauer & Walker 2001) and 
infection at a later age (Lauer & Walker 2001) are all 
associated with an increased risk of cirrhosis (Lauer & 
Walker 2001). Concomitant hepatitis B or HIV infec-
tion also increases the rate of development and preva-
lence of cirrhosis.  HIV co-infection has been shown to 
adversely affect treatment response rates and to in-
crease treatment discontinuation (Pearlman 2004).  
 
Testing for HCV 
Today‟s methods for diagnosing HCV (Loukatou et al. 
2015) have greatly increased accuracy over the „first-
generation‟ tests introduced after the identification of 
the HCV (Majid & Gretch 2002). Several types of tests 
are available for the various stages of HCV infection 
(Loukatou et al. 2014). 
 
Diagnosis 
Testing for HCV is usually undertaken in patients with 
known risk factors for infection, or who present with 
increased aminotransferase levels (Majid & Gretch 
2002). An enzyme immunoassay (EIA) is used to diag-
nose „seroconversion‟ caused by HCV infection 
(Majid & Gretch 2002). The EIA reacts with antibod-
ies produced by the immune system in reaction to 
HCV (Loukatou et al. 2015) infection to produce a 
positive result (Majid & Gretch 2002). If a confirmato-
ry test is required, a (more complex) polymerase chain 
reaction (PCR)-based technique is used (Majid & 
Gretch 2002). This is much more sensitive and may be 
required in, for example, immunosuppressed patients 
(Lauer & Walker 2001). 
 
Establishing viral load prior to treatment 
Quantitative assays are generally needed at this stage 
as the viral load before treatment begins can predict 
the chances of success (Boulaki et al. 2013). A low 
blood HCV level tends to favour an improved treat-
ment response (Majid & Gretch 2002). Techniques are 
based on one of the following: a) complexation of vi-
ral genomic material with complementary oligonucle-
otides followed by binding to an amplifier molecule 
(branched deoxyribonucleic acid) (Majid & Gretch 
2002), b) PCR technologies, c) generation of copy 
cDNA from viral RNA hybridised with a promoter 
region which is then used to generate multiple RNA 
copies which emit a „flash signal‟ on testing 
(transcription-mediated amplification [TMA]) and, d) 
combination of PCR and TMA technologies to give 
nucleic acid sequence-based amplification (NASBA) 
(Majid & Gretch 2002). The most sensitive methods 
are PCR-based; bDNA technology is the least sensi-
tive (Majid & Gretch 2002).  TMA is as sensitive as 
the best PCR technologies but is only used qualitative-
ly in clinics (Majid & Gretch 2002). 
 
Monitoring response to treatment 
HCV serum load is generally tested after 3 and 6 
months of treatment (Majid & Gretch 2002).  An unde-
tectable viral load at 6 months gives a high chance of a 
successful treatment outcome (Majid & Gretch 2002).  
The same methods used to evaluate pre-treatment virus 
levels are used to monitor treatment response. 
 
Diagnosing/Monitoring Liver Disease 
Two main techniques are used in tracking the progress 
of liver disease in HCV-infected patients. Alanine ami-
notransferase levels are a non-invasive, low-cost way 
of diagnosing liver disease; however this can be an 
unreliable marker, as levels are prone to fluctuation 
and may remain within „normal‟ limits even when liv-
er damage is present (Lauer & Walker 2001). A liver 
biopsy is by far the most accurate determinant of cur-
rent levels of hepatic damage and can also contribute 
to the assessment of a patient‟s prognosis; however the 
invasive nature of this procedure limits its use (Lauer 
& Walker 2001). 
 
HCV Genetics 
 
The HCV Genome 
HCV is a member of the family flaviviridae, which 
also encompasses the dengue, yellow fever and hepati-
tis G viruses (Lauer & Walker 2001, Papageorgiou et 
al. 2014, 2016, Vlachakis & Champeris Tsaniras 2016, 
Vlachakis et al. 2012, 2013).  The 9.6 kilobase genome 
shown above encodes over 3000 amino acids.  The 
genome is initially translated by ribosomes into a sin-
gle polyprotein (De Francesco et al. 2003) which is 
then processed into the ten functional protein products. 
Different areas of the genome exhibit differing rates of 
mutation (Lauer & Walker 2001). Two areas of the E2 
protein are known as „hypervariable‟, as they frequent-
ly mutate.  In contrast, the 5‟UTR is extremely highly 
conserved (around 90% sequence consistency) be-
tween HCV genotypes and subtypes, making it an ide-
al „target‟ for diagnostic testing (Majid & Gretch 
2002) and drug therapy. 
 
Genotypes 
By examining sequence similarities (Papangelopoulos 
et al. 2013), six distinct HCV genotypes can be identi-
fied – each with their own range of subtypes (Lauer & 
Walker 2001). There is over 30% genetic diversity be-
tween genotypes (Simmonds 2004), although much of 
this is localised to specific regions – such as the enve-
lope proteins – while many essential enzymes remain 
almost unaltered between genotypes.  This may be be-
cause envelope proteins constitute the portion of the 
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virus most likely to be recognised by the host immune 
system, and therefore mutations are selected for in a 
„Darwinian‟ process as they allow the virus to evade 
host immune responses.  Enzymes, on the other hand, 
cannot easily be dramatically altered as this could pre-
vent them from functioning. Between subtypes, a less-
er (20-25%) degree of genetic diversity is observed, 
and much of this can be accounted for by changes in 
the base sequence which result in synonymous coding 
(i.e. the sequence changes but still codes for the same 
amino acids) (Simmonds 2004). Genotypes 1a and 1b 
are the most common in the West (Simmonds 2004), 
with genotypes 2 (Lauer & Walker 2001) and 3 
(Simmonds 2004) seen over the same geographical 
area but less frequently; other genotypes are almost 
never seen here (Lauer & Walker 2001). 
 Genotype 3 has also been present over the 
whole of Asia for many years now (Pybus et al. 2005). 
In Egypt, a country which has the highest proportion 
of HCV infection in the world, genotype 4 predomi-
nates (Lauer & Walker 2001), whilst genotype 5 is 
frequently seen in South Africa (Simmonds 2004)  
(although genotypes 1 and 2 are common in the rest of 
Africa) (Pybus et al. 2005). Genotype 6, although pre-
viously only seen in Southeast Asia, has now also 
spread to Australia (Simmonds 2004).  
 Knowledge of the genotype (and subtype) of 
an HCV infection is useful in predicting treatment re-
sponses. Infection with strains 2 or 3 is known to be 
more amenable to treatment, while genotype 1 infec-
tion is more likely to require prolonged therapy and 
has lower successful treatment rate (Lauer & Walker 
2001). 
 
HCV Therapy - Current Treatments & Future 
Targets  
 
Current Treatments 
Due to the combination of a high number of infected 
persons and the poor success rates of current treat-
ments, there is an urgent need for new, more effective 
HCV treatments (Loukatou et al. 2015). Although sev-
eral areas have been identified for the development of 
new HCV therapies, Ribavirin together with pegylated 
interferon-α (PEG IFN-α; the 2a and 2b forms are both 
used) is the current treatment of choice for HCV infec-
tion (Pearlman 2004). Ribavirin, a guanosine analogue, 
is the only nucleoside analogue to have been identified 
as being useful in HCV treatment (Gordon & Keller 
2005). PEG IFN-α acts both as an antiviral (by inhibit-
ing replication) and immunomodulating (by enhancing 
the host immune response) agent (Gordon & Keller 
2005). Previously, „standard‟ IFN-α was used but at-
tachment of polyethylene glycol residues was found to 
increase both its activity and half-life (Pearlman 2004), 
therefore allowing a more effective treatment to be 
given less frequently.  
 Problems are often encountered when using 
the therapy above, not least of which is the fact that - 
even with optimal treatment regimes - response rates 
remain at a little over half of all patients treated. Even 
where treatment is successful, up to 50% of patients 
will relapse (i.e. the infection returns) (Walker 1999). 
Other problems include the high cost of treatment, the 
fact that PEG IFN-α can only be given by injection, the 
lower success rates with infections caused by geno-
types other than HCV genotype 2 or 3 and several side
-effects (Lauer & Walker 2001). 
 
Viral Life Cycle-Based Future Targets  
Due to the combination of a high number of infected 
persons and the poor success rates of current treat-
ments, there is an urgent need for new, more effective 
HCV treatments. Although several areas have been 
identified for the development of new HCV therapies, 
research directed at viral life cycle targets has the 
greatest possibility for producing a true cure for HCV. 
This is because, unlike other research areas such as 
antifibrotic agents (Pearlman 2004), a drug which 
blocks an essential step in the virus life cycle will pre-
vent replication and therefore „kill‟ the virus and allow 
the body to clear the infection. In addition, drugs 
aimed at virus-specific enzymes have a lower potential 
for adverse effects as (in theory) they should not affect 
host enzymes. Viral life-cycle targets have been the 
focus of most research and development (R&D) efforts 
that have been disclosed to date.  Here, only those tar-
gets which have already been the subjecs (Walker & 
Hong 2002) of published drug discovery efforts 
(Kandil et al. 2009, Walker 1999) will be discussed. 
 It should be noted that investigations into pos-
sible treatments have been severely limited by the lack 
of suitable small-animal or tissue culture models for 
HCV infection, even though bovine viral diarrhoea 
virus has been used in cell culture as a substitute for 
HCV during screening (Buckwold et al. 2003). Cur-
rently, the only widely accepted animal model availa-
ble is the chimpanzee, which has too many costs and 
ethical issues to be routinely used for identification of 
possible candidate drugs (Gordon & Keller 2005).  
However, new models have been and are still being 
developed which are revolutionising the area of anti-
HCV drug development and testing (Vlachakis et al. 
2013). A successful and fairly widely used subge-
nomic replicon system - where the virus genome has 
the areas coding for structural elements removed and 
different genes for replication control and marker re-
gions added (Papangelopoulos et al. 2013) - was de-
veloped for use as a cell culture system by Lohmann et 
al. in 1999. Small animal models have also been the 
focus of several research teams, resulting in the pro-
duction of transgenic mice with livers containing via-
ble chimeric human hepatic tissue (Mercer et al. 2001), 
although this approach - together with similar reports 
on HCV infection of tree shrews and transgenic mice - 
appears to have received less attention than cell culture 
models (Moradpour et al. 2002). 
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Structural envelop glycoproteins E1 and E2 
The structural proteins comprise the HCV viral capsid 
encoded by the core proteins and the envelope glyco-
proteins E1 and E2. The envelop glycoproteins are lo-
cated on the surface of virion and represent a multi-
functional complex of proteins, which operate a num-
ber of significant biological functions. Based on de-
scriptions bearing, they are heavily glycosylated with 
complex sugar moieties and represent critical determi-
nants for HCV entry into permissive cells and facilitat-
ing receptor binding. Moreover, the envelope structur-
al glycoproteins E1 and E2 mediate the fusion proce-
dure and entry into host cells membrane. The glyco-
proteins also contribute to virion assembly, bind host 
lipoproteins and apolipoproteins, and are the primary 
targets of the humoral immune response. Although 
these critical functions must be maintained, HCV en-
velop glycoproteins E1 and E2 are the targets of host 
adaptive immune response and must be changed in 
order to escape antigens detection, which is frequently 
mutate in viral replication. Until now, many studies 
have been performed in order to understand all aspects 
of HCV glycoproteins biology, including functionality, 
structure, genetic diversity and anti-genicity, and to 
use it as a potential vaccination strategies against HCV 
virus. 
 
Internal ribosomal entry sites (IRES)  
Contained within the 5‟-UTR of the HCV genome, the 
IRES allows binding of the viral genome to host ribo-
somes, which enables protein translation to be initiated 
(Majid & Gretch 2002). Drug discovery efforts to date 
have revealed antisense agents (which bind to the 
RNA sequence to prevent it from interacting with the 
ribosome), some small molecule inhibitors which may 
interact with ribosomal binding sites within the IRES, 
and ribozymes (Papageorgiou et al. 2014) which con-
tain antisense portions for targeting and catalytic se-
quences for genome destruction (Walker 1999). One of 
the most well-defined classes of small molecule inhibi-
tors is the phenazines (Wang et al. 2000), although 
current testing does not appear to have extended be-
yond in vitro evaluation. Several antisense oligonucle-
otides have been developed and tested (McCaffrey et 
al. 2003), and the ribozyme agent Heptazyme has en-
tered clinical trials - although its development has been 
halted after severe toxicity was seen in primates 
(Gordon & Keller 2005). Although this is a setback for 
ribozyme drugs / IRES targeting (Loukatou et al. 
2014), this remains an important target which may pro-
duce useful anti-HCV drugs in the future 
(Papageorgiou et al. 2014). 
 
NS5B (non-stractural protein) Rna-Dependent Rna 
polymerase  
This enzyme has been identified as a major target in 
the search for new anti-HCV drugs as it is both essen-
tial for replication (Chan et al. 2004) and has no host 
equivalent in non-infected cells. The genetic similari-
ties observed between this RNA-dependent RNA poly-
merase (RdRp) and other related polymerases has aid-
ed its characterisation, and crystal structures 
(Bressanelli et al. 1999) have now revealed that the 
HCV RdRp has a „classic‟ palm/fingers/thumb struc-
ture (Bressanelli et al. 1999, Chan et al. 2004, Lesburg 
et al. 1999, Walker & Hong 2002). The enzyme also 
has a large hydrophobic carboxy terminal (Bressanelli 
et al. 1999); this may mean that the enzyme is mem-
brane-bound in vivo (Papageorgiou et al. 2013). 
 The sequence of events catalysed by this en-
zyme (i.e. potential target processes for drug-based 
inhibition) is thought to run in the following order: 
template docking & nucleotide binding, initiation, 
elongation, termination andt emplate release 
(Bressanelli et al. 1999).  
Compounds so far reported as having anti-HCV RdRp 
activity can be easily divided into two classes: nucleo-
side and non-nucleoside inhibitors (Bressanelli et al. 
1999). Nucleoside inhibitors have previously proved 
very successful in the treatment of viral infections such 
as HIV but, of those in clinical use, only ribavirin has 
been found to show anti-HCV activity. Novel anti-
HCV nucleoside analogues have been identified and 
are generally thought to act either by preventing chain 
elongation or by causing problems with viral replica-
tion following incorporation into HCV RNA 
(Bressanelli et al. 1999). Non-nucleoside analogues, 
which may result in increased selectivity (nucleoside 
analogues could affect endogenous enzymes which 
utilise nucleic acid residues) of varying structures and 
potency have also been identified (Bressanelli et al. 
1999, McCaffrey et al. 2003, McKercher et al. 2004). 
However, none of the compounds so far discovered 
appear to have entered clinical testing (Vlachakis et al. 
2015). 
 
NS3-4A (non-stractural protein protease)  
The amino terminal (Vlachakis et al. 2014) end 1/3rd 
of the NS3 protein has a serine protease function 
(Moradpour et al. 2002), which requires the NS4A 
protein as a cofactor to increase stability and activity 
(Gordon & Keller 2005). The structure of NS3, both 
alone (Barbato et al. 1999, Love et al. 1996) and in 
complex with NS4A (McCoy et al. 2001, Yan et al. 
1998) has been fully elucidated by X-ray crystallog-
raphy and NMR spectroscopy. This revealed that NS3 
portion forms two six-stranded β barrels connected by 
short loops (Love et al. 1996) and preceded by a 28 
amino acid hydrophobic region (amino terminal) 
(Barbato et al. 1999). A zinc binding site is formed by 
one histidine and three cysteine residues (Love et al. 
1996).  Interacting with the NS4A protein allows the N
-terminal 28 amino acids to form an α helix and β 
strand (in the absence of NS4A, no structural features 
are seen) (Barbato et al. 1999) and also causes the NS3 
D1 β strand to interact with a second region of the 
complex to take on a structural support role (Barbato et 
al. 1999). This high level of structural information 
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(Vlachakis et al. 2014), together with the essential na-
ture of the enzyme (it is required for NS4B, NS5A and 
NS5B formation) has made it an attractive target 
(Moradpour et al. 2002). However, the nature of the 
enzyme active site means that progress has been slow 
to date, as the site is a) unlike other members of the 
chymotrypsin superfamily (and therefore cannot be 
targeted by known inhibitors of this family of en-
zymes) (Gordon & Keller 2005), b) is wide and ex-
posed, with few features which can be exploited for 
drug binding (Walker 1999) and c) unusually requires 
a cysteine residue or analogue in the P1 residue bind-
ing pocket (Walker 1999) 
 Despite this, several inhibitors of the NS3-4A 
serine protease have been designed, which can be 
loosely assigned to 3 groups (Gordon & Keller 2005).  
The first, and perhaps most obvious, are the product 
analogues (Gordon & Keller 2005). Initially, larger 
peptide mimics, such as hexapeptides (Gordon & Kel-
ler 2005, Johansson et al. 2003), were developed alt-
hough it was subsequently discovered that smaller di- 
and tripeptides and their analogues were also effective 
(Gordon & Keller 2005, Johansson et al. 2003, Nizi et 
al. 2004). The second group of compounds are small 
molecules which inhibit protease activity via non-
competitive mechanisms (Gordon & Keller 2005). The 
final group consists of large RNA polymers (Gordon 
& Keller 2005). To date, the most successful com-
pound is BILN 2061 (developed by Boehringer Ingel-
heim), a macrocyclic peptidomimetic developed from 
the N-terminal cleavage products of reactions cata-
lysed by the serine protease, which has entered clinical 
trials (Lamarre et al. 2003). 
 
NS3-4A (non-stractural protein helicase)  
The carboxy terminal two thirds of the NS3 enzyme 
constitutes an RNA helicase/nucleoside triphosphatase 
(NTPase) function (Kim et al. 1995) which has also 
been a major target of drug discovery efforts.  In vivo 
(Spyropoulos et al. 2012), the enzyme is used to sepa-
rate negative-stranded RNA (synthesised after infec-
tion of a cell) from the positive-stranded RNA (found 
packaged in infective virions) with which it would au-
tomatically have formed a double-stranded complex 
(Gordon & Keller 2005). This enables the virus to use 
cellular machinery to synthesise more positive-
stranded RNA – using the negative-stranded form as a 
template – for inclusion in infective virus particles 
(Gordon & Keller 2005). The motion of unwinding 
double-strand RNA as performed by NS3 helicase ap-
pears to proceed in steps of 18 kilobases (kb) along the 
genome. One part of the enzyme moves 18kb along the 
double-stranded RNA and stops, after which a second 
part follows behind and unwinds the double helix. The 
enzyme‟s action then „pauses‟ before repeating the 
process on the next section of RNA (Bianco 2004). 
The energy for this comes from the breakdown of nu-
cleoside triphosphates (usually adenosine triphosphate) 
(Bianco 2004) by the enzyme‟s NTPase functionality.  
It is interesting to note that HCV helicase, unlike many 
similar enzymes, exhibits poor substrate specificity 
(Vlachakis 2007) and is capable of unwinding RNA/
RNA, DNA/DNA and RNA/DNA duplexes (Gordon 
& Keller 2005). The NTPase function has a similarly 
low specificity requirement and will hydrolyse all en-
dogenous forms of NTPs as well as synthetic acyclic 
NTPs and nucleoside analogues (Borowski et al. 
2002). 
 
Conclusion  
 
The crystal structure of HCV helicase (Loukatou et al. 
2014) has been fully elucidated, both as the enzyme 
alone (Cho et al. 1998, Yao et al. 1997) and in com-
plex with a single-stranded DNA oligonucleotide (Kim 
et al. 1998).  Three domains have been observed, to-
gether with binding clefts for RNA and NTPs (Cho et 
al. 1998) domains 1 and 2 show great similarity both 
in their structure (Vangelatos et al. 2009) and in inter-
actions with genetic material; both contain α helices 
either side of a six-stranded parallel β sheet (domain 1 
also has a seventh, antiparallel strand) (Kim et al. 
1998). In contrast, domain 3 is largely composed of α 
helices with two antiparallel β strands (Kim et al. 
1998). Domains 1 and 3 are closely associated via 
packaging of various α helices, while domain 2 is more 
loosely bound to both (Spyropoulos et al. 2012).  This 
allows some limited movement of domain 2, and 
leaves a single large cleft at the domain 1/domain 2 
and domain 2/domain 3 interfaces (Kim et al. 1998). 
 This is proposed to be the binding site for 
RNA in vivo (Cho et al. 1998), with the mobility of 
domain 2 thought to be involved in allowing unwind-
ing (Yao et al. 1997). A phosphate binding loop 
(Spyropoulos et al. 2012), similar to those seen in re-
lated ATPases is present in the amino terminal region 
of domain 1 which suggests that the NTPase function 
is located here (Kim et al. 1998). 
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